Effectiveness of Botulinum toxin Type A injection (Dysport®) to restore quadriceps muscle balance and improve chronic knee pai

Phase 1

Active, not recruiting

• Conditions: Chronic anterior knee pain?; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12605000775617
• Lead Sponsor: Dr BJ Singer, School of Surgery and Pathology, The University of Western AustraliaMedical Research Foundation Building, Level 2, Rear 50 Murray Street, Perth, WA 6000

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-12-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Anterior or retropatellar pain on at least two of the following: prolonged sitting, stairs, squat, running, kneeling and hopping/jumping unrelated to a recent traumatic incident no surgical intervention (arthroscopic investigation or menisectomy allowed).

Exclusion Criteria

History of recurrent patella dislocation/subluxationClinical evidence of meniscal lesion, ligamentous instability, traction apophysitis around the patello-femoral complex, or patellar tendon pathology Radiographically determined osteoarthrotic changes of the PFJ Obesity BMI >30Previous BTXA injection within 3 months or any history of adverse reaction to BTXADisorders producing disturbed neuromuscular transmission (eg.myasthenia gravis)Concurrent use of aminoglycosides (potential for interaction with BTXA)History of infectious diseases or active rheumatoid arthritis.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Self-reported knee related disability and quality of life [Anterior Knee Pain Scale][Comparison of AKPS scores at 12 week and 24 weeks with average of 3 baseline measures];Timing of muscle onsets of VM/VL and ratio of VL:VM amplitude during a standardized stepping task [EMG]?[Comparison of timing of onsets at 12 week and 24 weeks with average of 3 baseline measures]

Secondary Outcome Measures

Name	Time	Method
Isometric knee extension force at 30° and 90° knee flexion [digital force dynamometry].[At 2, 6, 12, 18 and 24 weeks post injection, final measures at 1 year post entry to study.];Patella congruence and VM/VL cross sectional area [CT imaging][At 12 weeks compared with baseline measures.]